Financing now in place for 3 years.... I think that today's news is good. Financing for testing is now in place for 3 years. Furthermore, the April 30 MD&A gave us the following, referring to the Feb results ;
" the results did not reach the level of statistical significance required to reach definitive conclusions due to a wide dispersion of data in the untreated controls groups and other test implementation issues identified by the investigators at OHRI".
This tells me that there was no problem detected with the drug: just with the way the tests were handled. So, with financing in place, we are back in the saddle, with an excellent product.
Mr Bryden is "going all in". That should tell us something..........